Journal of Medical Virology · 2015 · 11 citations · 7 references
PharmacyGynecologyInfectious DiseasesMolecular VirologyReproductive MedicineVirologyAntiviral PharmacologyAntiviral TherapySexually Transmitted InfectionsVaginal Dosage FormsVaginal Drug DeliveryHpv TreatmentIntravaginal TherapySerious Adverse EventsVaginal Antiviral FormulationsVaginal MicroenvironmentVaginal Safety
Currently, there is no specific antiviral therapy for treatment of HPV infection. Jiang and colleagues previously reported that anhydride-modified proteins have inhibitory activities against multiple viruses including HPV. Here, we evaluated the safety of 3-hydroxyphthalic anhydride-modified bovine beta-lactoglobulin, designated JB01, vaginally applied in women infected by high-risk HPV. After the vaginal application of JB01 in 38 women for 3 months, no serious adverse events were reported, and normalization of the vaginal micro-environment has been observed. It can be concluded that JB01-BD is safe for vaginal use in HPV-infected women, suggesting its potential application for the treatment of HPV infection.
7
[Trend analysis and projection of cancer incidence in China between 1989 and 2008].
Wanqing Chen, Rongshou Zheng, Hongmei Zeng et al. · PubMed · 2012 · 58 citations